Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines

Strong recommendation with high certainty of clinical evidence underscores proven efficacy, safety, and tolerability of ZORYVE cream as a ...
Monthly Prescribing Reference

Zoryve Cream 0.15% for Atopic Dermatitis Now Available

Credit: Arcutis. Zoryve cream contains roflumilast, a phosphodiesterase type 4 inhibitor. Zoryve (roflumilast) cream 0.15% is now available for the topical treatment of mild to moderate atopic ...

Arcutis Biotherapeutics (ARQT) Presents Positive Phase 2 Data for ZORYVE Cream in Infants

Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) is one of the 10 Overlooked Growth Stocks to Buy Now. Arcutis Biotherapeutics Inc.
Healio

Patients with atopic dermatitis maintain improvement post-treatment with Vtama cream

Please provide your email address to receive an email when new articles are posted on . Approximately 81% of Vtama-treated patients achieved EASI 75. 51.2% of patients achieved complete disease ...
The American Journal of Managed Care

Ruxolitinib Cream and Atopic Dermatitis at AAD 2025

A panelist discusses how real-world data presented at the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) demonstrates that initiating ruxolitinib cream therapy for atopic dermatitis ...
Healio

Vtama cream approved for treatment of psoriasis, atopic dermatitis in Japan

Please provide your email address to receive an email when new articles are posted on . Dermavant Sciences partner, Japan Tobacco, received approval for Vtama cream 1% in Japan. Approved indications ...
Seeking Alpha

Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis

Once-daily, effective, safe, and well-tolerated ZORYVE cream now commercially available Provides rapid clearance of atopic dermatitis signs and symptoms and significant reduction in itch, and can be ...
Business Wire

Dermavant Announces Positive Data from the ADORING Phase 3 Development Program in Atopic Dermatitis with VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 ...

- 80.7% (574/711) of patients achieved EASI75 (at least a 75% reduction in disease burden) in an integrated analysis of all the ADORING Program studies - - 77.9% (218/280) of patients ≥12 years old ...
Nasdaq

Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference

New data from the Phase 3 INTEGUMENT-OLE long-term open label study show durable improvement in the signs and symptoms of atopic dermatitis (AD), including almost half of participants achieving no or ...
Business Wire

Dermavant Presents ADORING 3 LTE Final Data on Complete Skin Clearance and Treatment-Free Interval for VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as Two ...

- The majority of patients, 51.9% (378/728), entered with or achieved complete disease clearance (vIGA-AD™=0) in the 48-week ADORING 3 open-label LTE study. - Most patients, 81.6% (594/728), entered ...
Monthly Prescribing Reference

Zoryve Cream 0.15% Approved for Atopic Dermatitis

Credit: Arcutis. The approval was supported by data from the phase 3 INTEGUMENT-1 and INTEGUMENT-2 trials. The Food and Drug Administration (FDA) has approved Zoryve ® (roflumilast) cream 0.15% for ...